InVivo Biosystems: Funding, Investors & Team (Oct 2026)
InVivo Biosystems is a biotechnology company that offers genome editing and in vivo analytical services to speed up drug discovery and development. They specialize in creating customized genome-edited models of C. elegans and zebrafish to aid research in neurological, metabolic, and rare monogenic diseases. The company was formed from the merger of NemaMetrix and Knudra Transgenics and has developed unique technologies, such as the RapidGen™ preclinical platform, to connect cell culture and rodent models. This platform allows for early compound screening, toxicity testing, and efficacy analysis, providing valuable biological data for drug development decisions. InVivo Biosystems caters to pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services like CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing. The company has multiple global patents for its genome editing technologies and continues to lead in preclinical development innovation.
InVivo Biosystems has raised $3.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Apr 2025.
InVivo Biosystems Company Profile and Key Stats
Latest funding round on record: Apr 2025.
InVivo Biosystems Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
InVivo Biosystems raised $3.0M in an undisclosed round announced in Jan 2024.
1.3 years later, an undisclosed round was announced in Apr 2025 with no disclosed amount.
InVivo Biosystems Founders and Leadership Team
Contact details for the InVivo Biosystems team: 1 of 2 have an email address on file.
Start 14-day free trial →InVivo Biosystems Funding Compared to Other Biotechnology Startups
Funded Startups Like InVivo Biosystems in Biotechnology and Eugene
Companies Similar to InVivo Biosystems
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
InVivo Biosystems Funding FAQs
What does InVivo Biosystems do?
InVivo Biosystems is a biotechnology company that offers genome editing and in vivo analytical services to speed up drug discovery and development. They specialize in creating customized genome-edited models of C. elegans and zebrafish to aid research in neurological, metabolic, and rare monogenic diseases. The company was formed from the merger of NemaMetrix and Knudra Transgenics and has developed unique technologies, such as the RapidGen™ preclinical platform, to connect cell culture and rodent models. This platform allows for early compound screening, toxicity testing, and efficacy analysis, providing valuable biological data for drug development decisions. InVivo Biosystems caters to pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services like CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing. The company has multiple global patents for its genome editing technologies and continues to lead in preclinical development innovation.
How much funding has InVivo Biosystems raised?
InVivo Biosystems has raised $3.0M across 2 rounds on record.
When did InVivo Biosystems last raise funding?
InVivo Biosystems' most recent funding round on record was announced in Apr 2025. The amount was not disclosed.
Who founded InVivo Biosystems?
FundedIQ lists Janis Weeks (Founder), Matt Beaudet (Founder) at InVivo Biosystems.
Where is InVivo Biosystems headquartered?
InVivo Biosystems is based in Eugene, Oregon, United States.
How many employees does InVivo Biosystems have?
InVivo Biosystems is in the 51-100 employee band.
About FundedIQ's InVivo Biosystems Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for InVivo Biosystems is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.